Vildagliptin
£45.00 10mg
Dipeptidyl peptidase IV (DPP-IV) inhibitor.
Vildagliptin, also known as LAF237, is a potent and selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin inhibits the inactivation of glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP) by DPP-IV, allowing GLP-1 and GIP to potentiate the secretion of insulin and suppress glucagon release in the pancreas. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity in type 2 diabetes.
Please contact us for availability.
Additional information
| Other Names | LAF237 |
|---|---|
| Three Letter Sequence | 1-[2-[(3-Hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-2S-pyrrolidinecarbonitrile |
| Molecular Weight | 303.4 |
| Molecular Formula | C17H25N3O2 |
| Sequence | 1-[2-[(3-Hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-2S-pyrrolidinecarbonitrile |
| Solubility | Soluble in water |
| Appearance | White solid |
| Storage | Store desiccated, frozen and in the dark |
| Purity | 98% by TLC |